| Literature DB >> 35154028 |
Marzieh Zohrabi1,2, Laleh Dehghan Marvast3, Mahin Izadi1,2, Seyed Alireza Mousavi4, Behrouz Aflatoonian2,5,6.
Abstract
Neisseria gonorrhoeae and Chlamydia trachomatis are the most common causes of bacterial sexually transmitted diseases (STDs) with complications in women, including pelvic inflammatory disease (PID), ectopic pregnancy, and infertility. The main concern with these infections is that 70% of infected women are asymptomatic and these infections ascend to the upper female reproductive tract (FRT). Primary infection in epithelial cells creates a cascade of events that leads to secretion of pro-inflammatory cytokines that stimulate innate immunity. Production of various cytokines is damaging to mucosal barriers, and tissue destruction leads to ciliated epithelial destruction that is associated with tubal scarring and ultimately provides the conditions for infertility. Mesenchymal stem cells (MSCs) are known as tissue specific stem cells with limited self-renewal capacity and the ability to repair damaged tissues in a variety of pathological conditions due to their multipotential differentiation capacity. Moreover, MSCs secrete exosomes that contain bioactive factors such as proteins, lipids, chemokines, enzymes, cytokines, and immunomodulatory factors which have therapeutic properties to enhance recovery activity and modulate immune responses. Experimental studies have shown that local and systemic treatment of MSC-derived exosomes (MSC-Exos) suppresses the destructive immune response due to the delivery of immunomodulatory proteins. Interestingly, some recent data have indicated that MSC-Exos display strong antimicrobial effects, by the secretion of antimicrobial peptides and proteins (AMPs), and increase bacterial clearance by enhancing the phagocytic activity of host immune cells. Considering MSC-Exos can secrete different bioactive factors that can modulate the immune system and prevent infection, exosome therapy is considered as a new therapeutic method in the treatment of inflammatory and microbial diseases. Here we intend to review the possible application of MSC-Exos in female reproductive system bacterial diseases.Entities:
Keywords: Chlamydia trachomatis; MSC-derived exosomes; Neisseria gonorrhoeae; antibacterial properties; antimicrobial effects; female infertility; mesenchymal stem cells
Year: 2022 PMID: 35154028 PMCID: PMC8834364 DOI: 10.3389/fmicb.2021.785649
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
FIGURE 1Direct mechanisms of MSC-mediated bacterial killing, MSC exert direct antibacterial effects due to host defense peptides or AMPs. MScs can mediate bacterial killing by disrupting the integrity of the bacterial membrane, creating pores in the bacterial membrane, preventing of iron uptake, inhibiting biofilm formation, depleting tryptophan in microorganisms, and halting the growth of bacteria. IDO pathways, Indoleamine 2,3 dioxygenase; iNOS pathways, inducible nitric oxide synthase; NO, nitric oxide.
FIGURE 2The antibacterial effects of MSC can be indirectly mediated by increasing phagocytic activity of macrophages and neutrophils. These cells can also induce immunomodulatory effects by modulating immune responses and regulating cytokine homeostasis. MVs, microvesicles; DC, dendritic cell; NKC, natural killer cell; NET, neutrophil extracellular trap; IFN, interferon; TNF, tumor necrosis factor; NO, nitric oxide; PGE2, prostaglandin E2; TGF, transforming growth factor; IDO, indoleamine 2,3 dioxygenase; Treg, T regulatory cell; Ig, immunoglobulin.
Antibacterial and Immunomodulatory Effects of MSCs and MSC-Exos in in vitro and in vivo studies.
| Study type | Source of MSC | Outcomes | References |
| AT-MSC | ↑ Cathelicidin secretion |
| |
| BM-MSC, AT-MSC | ↑ Enhance antibiotic sensitivity |
| |
| BM-MSC, AT-MSC, EM-MSC | ↓ Growth of |
| |
| BM-MSC | ↓ Genes expression of apoptosis |
| |
| PB-MSC | ↓ Growth of |
| |
| HU-MSC | ↑ Keratinocyte growth factor (KGF) |
| |
| BM-MSC | ↓ Leukocyte infiltration in ovaries |
| |
| WJ-MSC | ↓ TNF-α |
| |
| hUC-MSC | ↓ Macrophage infiltration |
| |
| FL-MSC-Exos | ↓ Proliferation, activation, and cytotoxicity of NK cells |
| |
| UC-MSCs-EVs | ↓TNF-α, |
| |
| hU-MSC-Exos | ↑Restored ovarian phenotype and function |
| |
| A-MSC- MVs | ↓Apoptosis rate |
| |
| BM-MSC-EV | ↑M2 macrophage marker expression |
| |
| BM-MSC-Exos | ↑IL-10 |
|
MSC, mesenchymal stem cell; AT-MSC, adipose tissue-MSC; HU-MSC, human-MSC; BM-MSC, bone marrow-MSC; EM-MSC, endometrium-MSC; PB-MSC, peripheral blood-MSC; FL-MSC, fetal liver-MSC; WJ-MSC, wharton’s jelly; hUC-MSC, human umbilical cord-MSC; A-MSC, amniotic-MSC; MCP-1, monocyte chemoattractant protein-1; CCL5, chemokine ligand-5; FT, Fallopian tube; IUAs, intrauterine adhesions.